

COMPANY ANNOUNCEMENT

Extension of Offer to Minority Equity Holders

Further to the offer made to minority share and option holders in Prima Biomed Limited subsidiaries released to the ASX on 10th August 2005, the offer has been extended for a period of 2 weeks to Monday 26th of September 2005, closing at 5.00pm.

Following processing of the acceptances received from share and option holders to date, Prima will have increased ownership to the following amounts:

- CancerVac Pty Ltd 100% of equity
- Panvax Ltd 100% of shares, 96.44% of options
- Oncomab Pty Ltd 100% of equity
- Arthron Pty Ltd 99.84% of shares, and 92.37% of options

About Prima BioMed Ltd

Prima BioMed (ASX: PRR) is a biotechnology company based in Melbourne and is developing technologies in the fields of immunology and cancer immunotherapy originating from the Austin Research Institute in Melbourne, Australia.

For further information, visit www.primabiomed.com.au